Platelet-rich plasma outcomes in knee osteoarthritis are associated with the amount of total deliverable platelets: A systematic review and meta-analysis.
Nicholas Hooper, Shane Shapiro, Vineet Paidsetty, Aydin Azarpey, Alexa Jindal, Kenneth Mautner, Kirk Easley, Don Buford, Walter Sussman, Prathap Jayaram
{"title":"Platelet-rich plasma outcomes in knee osteoarthritis are associated with the amount of total deliverable platelets: A systematic review and meta-analysis.","authors":"Nicholas Hooper, Shane Shapiro, Vineet Paidsetty, Aydin Azarpey, Alexa Jindal, Kenneth Mautner, Kirk Easley, Don Buford, Walter Sussman, Prathap Jayaram","doi":"10.1002/pmrj.13455","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The goal of this study was to examine if differing platelet counts in platelet-rich plasma (PRP) formulations affected overall pain and function outcomes when compared to hyaluronic acid or placebo control saline injections.</p><p><strong>Design/methods: </strong>We conducted a systematic review and meta-analysis (International Prospective Register of Systematic Reviews CRD42022340057) evaluating randomized controlled trials comparing injections of PRP to hyaluronic acid (HA) or saline (NS) control in patients with mild or moderate knee osteoarthritis. All studies used a validated outcome measure that examined pain, function, or overall patient global assessment. Study PRP interventions were subclassified as investigating the total number of platelets delivered in a low dose (1-5 billion total deliverable platelets), moderate dose (5-10 billion total deliverable platelets), or high dose (greater than 10 billion total deliverable platelets) injected into the joint.</p><p><strong>Results: </strong>A total of 32 trials met inclusion criteria. All three PRP groups had significant improvements in validated patient-reported outcomes when compared to HA. Both the \"low\" and \"high\" platelet count groups resulted in a moderate effect size, respectively (standardized mean difference [SMD] = .47; 95% confidence interval [CI] .05-0.89, p < .01; SMD = .68; 95% CI .26-1.09, p < .01). Only the \"moderate\" (SMD = 1.48; 95% CI .71-2.58 p < .01) platelet count group resulted in large effect size on validated patient-reported outcomes. When compared to NS, all three PRP groups resulted in significant large effect sizes when examining pain reduction.</p><p><strong>Conclusions: </strong>When compared to HA, PRP with platelet counts between 1 and 10 billion total deliverable platelets may result in a larger decrease in pain symptoms when compared to platelet counts greater than 10 billion at 6 months. In addition, platelet counts between 5 and 10 billion total deliverable platelets may be associated with greater improvement in functional outcomes.</p>","PeriodicalId":20354,"journal":{"name":"PM&R","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PM&R","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pmrj.13455","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"REHABILITATION","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The goal of this study was to examine if differing platelet counts in platelet-rich plasma (PRP) formulations affected overall pain and function outcomes when compared to hyaluronic acid or placebo control saline injections.
Design/methods: We conducted a systematic review and meta-analysis (International Prospective Register of Systematic Reviews CRD42022340057) evaluating randomized controlled trials comparing injections of PRP to hyaluronic acid (HA) or saline (NS) control in patients with mild or moderate knee osteoarthritis. All studies used a validated outcome measure that examined pain, function, or overall patient global assessment. Study PRP interventions were subclassified as investigating the total number of platelets delivered in a low dose (1-5 billion total deliverable platelets), moderate dose (5-10 billion total deliverable platelets), or high dose (greater than 10 billion total deliverable platelets) injected into the joint.
Results: A total of 32 trials met inclusion criteria. All three PRP groups had significant improvements in validated patient-reported outcomes when compared to HA. Both the "low" and "high" platelet count groups resulted in a moderate effect size, respectively (standardized mean difference [SMD] = .47; 95% confidence interval [CI] .05-0.89, p < .01; SMD = .68; 95% CI .26-1.09, p < .01). Only the "moderate" (SMD = 1.48; 95% CI .71-2.58 p < .01) platelet count group resulted in large effect size on validated patient-reported outcomes. When compared to NS, all three PRP groups resulted in significant large effect sizes when examining pain reduction.
Conclusions: When compared to HA, PRP with platelet counts between 1 and 10 billion total deliverable platelets may result in a larger decrease in pain symptoms when compared to platelet counts greater than 10 billion at 6 months. In addition, platelet counts between 5 and 10 billion total deliverable platelets may be associated with greater improvement in functional outcomes.
期刊介绍：
Topics covered include acute and chronic musculoskeletal disorders and pain, neurologic conditions involving the central and peripheral nervous systems, rehabilitation of impairments associated with disabilities in adults and children, and neurophysiology and electrodiagnosis. PM&R emphasizes principles of injury, function, and rehabilitation, and is designed to be relevant to practitioners and researchers in a variety of medical and surgical specialties and rehabilitation disciplines including allied health.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
